头孢哌酮/舒巴坦联合盐酸莫西沙星治疗重症肺炎的临床效果

Clinical effect of Cefoperazone/Sulbactam combined with Moxifloxacin Hy-drochloride in the treatment of severe pneumonia

目的探讨头孢哌酮/舒巴坦联合盐酸莫西沙星治疗重症肺炎的临床效果。方法选择2014年2月~2017年1月在我院诊断治疗的108例重症肺炎患者,依据治疗措施不同进行分组,对照组50例和头孢哌酮/舒巴坦联合盐酸莫西沙星组58例,观察两组重症肺炎患者治疗前后的炎症指标、白细胞计数水平情况和临床疗效情况。结果两组患者治疗前的白细胞(WBC)、C反应蛋白(CRP)、降钙素原(PCT)情况比较,差异无统计学意义(P>0.05),治疗后对照组和头孢哌酮/舒巴坦联合盐酸莫西沙星组的PCT、WBC、CRP均低于治疗前,差异有统计学意义(P<0.05),头孢哌酮/舒巴坦联合盐酸莫西沙星组治疗后的PCT、WBC、CRP均低于对照组,差异有统计学意义(P<0.05)。头孢哌酮/舒巴坦联合盐酸莫西沙星组的临床总有效率高于对照组,差异有统计学意义(P<0.05)。结论头孢哌酮/舒巴坦联合盐酸莫西沙星治疗重症肺炎患者的临床症状改善明显,效果良好,值得临床推广应用。

Objective To investigate the clinical effect of Cefoperazone/Sulbactam combined with Moxifioxacin Hydrochloride in the treatment of severe pneumonla.Methods 108 patients with severe pneumonia diagnosed and treated in our hospital from February 2014 to January 2017 were divided into control group （50 cases） and Moxifloxacin Hydroehloride combined with Cefoperazone/Sulbaetam group （58 cases） according to the different treatment measures.The inflammation index,white blood cell count and clinical efficacy of the two groups of patients with severe pneumonia before and after treatment were observed.Results There was no significant difference in PCT,WBC and CRP between the two groups before treatment（P〈0.05）.After treatment,the levels of PCT,WBC and CRP in the control group and Cefoperazone/Sulbactam combined Moxifloxacin Hydroehloride group were lower than those before treatment （P〈0.05）.After treatment, the levels of PCT,WBC and CRP in Cefoperazone/Sulbactam combined Moxifloxacin Hydrochloride group were lower than those in the control group （P〈0.05）.The total effective rate of Cefoperazone/Sulbactam combined with Moxifloxaein Hydrochloride group was higher than that of the control group（P〈0.05）.Conclusion In the treatment of severe pneumonia patients,Cefoperazone/Sulbactam combined with Moxifloxaein Hydrochloride greatly improves the clinical symptoms in a favorable effect,which is worthy of clinical application and promotion.